The US amino acid metabolism disorder drug market is supported by advanced newborn screening programs, strong rare disease research initiatives, and a well-established pharmaceutical industry. Increasing adoption of precision medicine, favorable regulatory support for orphan drugs, and growing awareness of inherited metabolic disorders continue to drive demand for specialized therapies across...